The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Open accessAbstract
A fresh look at glutamine targeting: Glutamine is essential for tumor growth and has long been an attractive therapeutic target for cancer researchers. Some attempts at blocking glutamine metabolism in cancer patients resulted in toxicity, prompting Leone et al. to develop an innovative approach to reduce general side effects. They designed a prodrug form (JHU083) of the glutamine antagonist 6-diazo-5-oxo- l -norleucine (DON), which is administered in an inert state but then preferentially activated by enzymes enriched in the tumor microenvironment. JHU083 simultaneously shut down glycolysis and oxidative phosphorylation in mouse cancer cells while enhancing T cell oxidative phosphorylation and anticancer immune responses. Science , this issue p. 1013
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study discovered a prodrug (JHU083) of the glutamine antagonist DON, which was designed to selectively become activated inside a tumor.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [200]
In the citing paper
“The researchers showed that blocking glutamine metabolism through JHU083 not only suppressed tumor cell metabolism but also mitigated the tumor microenvironment, which is hostile to the immune response due to its hypoxic, acidic, and nutrient-depleted conditions, unleashing the natural antitumor T cell response.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [200]
In the citing paper
“They also confirmed that concurrent treatment with JHU083 and anti-PD-1 checkpoint inhibitor improved the antitumor effects compared with anti-PD-1 treatment alone, suggesting the presence of metabolic plasticity between cancer cells and effector T cells, which could be exploited as a metabolic checkpoint for cancer immunotherapy200.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [200]
In the citing paper
“recent advances have optimized DON as a pro-drug with pharmacokinetic properties that increase tumor targeting203, including an orally available analog with promising pre-clinical results in murine PDAC models204”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [203]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation
Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L. L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.021 · Cited by 2,140
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development
van der Windt, G. J. W., Everts, B., Chang, C.-H., Curtis, J. D., Freitas, T. C., Amiel, E., Pearce, E. J., & Pearce, E. L. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.007 · Cited by 1,540
The CD28 Signaling Pathway Regulates Glucose Metabolism
Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H., & Thompson, C. B. (2002) · Immunity · doi:10.1016/s1074-7613(02)00323-0 · Cited by 1,475
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0507 · Cited by 1,435
Fueling Immunity: Insights into Metabolism and Lymphocyte Function
Pearce, E. L., Poffenberger, M. C., Chang, C.-H., & Jones, R. G. (2013) · Science · doi:10.1126/science.1242454 · Cited by 1,363
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69600 · Cited by 1,262
Metabolic Regulation of T Lymphocytes
MacIver, N. J., Michalek, R. D., & Rathmell, J. C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095956 · Cited by 1,244
Cancer's Molecular Sweet Tooth and the Warburg Effect
Kim, J., & Dang, C. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1501 · Cited by 1,233
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C., Fuerth, B. J., Viollet, B., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.001 · Cited by 949
Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer
Davidson, S. M., Papagiannakopoulos, T., Olenchock, B. A., Heyman, J. E., Keibler, M. A., Luengo, A., Bauer, M. R., Jha, A. K., O’Brien, J. P., Pierce, K. A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.007 · Cited by 737
Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine
Zhang, J., Pavlova, N. N., & Thompson, C. B. (2017) · The EMBO Journal · doi:10.15252/embj.201696151 · Cited by 651
T cell stemness and dysfunction in tumors are triggered by a common mechanism
Vodnala, S. K., Eil, R., Kishton, R. J., Sukumar, M., Yamamoto, T. N., Ha, N.-H., Lee, P.-H., Shin, M., Patel, S. J., Yu, Z., et al. (2019) · Science · doi:10.1126/science.aau0135 · Cited by 552
Pyruvate carboxylase is critical for non–small-cell lung cancer proliferation
Sellers, K., Fox, M. P., Bousamra, M., Slone, S. P., Higashi, R. M., Miller, D. M., Wang, Y., Yan, J., Yuneva, M. O., Deshpande, R., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci72873 · Cited by 497
Pyruvate carboxylase is required for glutamine-independent growth of tumor cells
Cheng, T., Sudderth, J., Yang, C., Mullen, A. R., Jin, E. S., Matés, J. M., & DeBerardinis, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016627108 · Cited by 475
Metabolic pathways in T cell fate and function
Gerriets, V. A., & Rathmell, J. C. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.01.010 · Cited by 444
Utter, M. F., & KEECH, D. B. (1963) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67873-1 · Cited by 440
S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate
Tyrakis, P. A., Palazon, A., Macias, D., Lee, K. L., Phan, A. T., Veliça, P., You, J., Chia, G. S., Sim, J., Doedens, A., et al. (2016) · Nature · doi:10.1038/nature20165 · Cited by 433
Zhao, E., Maj, T., Kryczek, I., Li, W., Wu, K., Zhao, L., Wei, S., Crespo, J., Wan, S., Vatan, L., et al. (2016) · Nature Immunology · doi:10.1038/ni.3313 · Cited by 405
Self-citationSiska, P. J., Beckermann, K. E., Mason, F. M., Andrejeva, G., Greenplate, A. R., Sendor, A. B., Chiang, Y.-C. J., Corona, A. L., Gemta, L. F., Vincent, B. G., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93411 · Cited by 389
Balmer, M. L., Ma, E. H., Bantug, G. R., Grählert, J., Pfister, S., Glatter, T., Jauch, A., Dimeloe, S., Slack, E., Dehio, P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.016 · Cited by 361
Acetate Promotes T Cell Effector Function during Glucose Restriction
Qiu, J., Villa, M., Sanin, D. E., Buck, M. D., O’Sullivan, D., Ching, R., Matsushita, M., Grzes, K. M., Winkler, F., Chang, C.-H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.022 · Cited by 342
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
Prendergast, G. C., Malachowski, W. P., Mondal, A., Scherle, P., & Muller, A. J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 277
We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine
Lemberg, K. M., Vornov, J. J., Rais, R., & Slusher, B. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1148 · Cited by 234
Self-citationTargeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
Kouidhi, S., Ayed, F. B., & Elgaaïed, A. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00353 · Cited by 195
Horton, B. L., Williams, J. B., Cabanov, A., Spranger, S., & Gajewski, T. F. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0249 · Cited by 170
Domain Architecture of Pyruvate Carboxylase, a Biotin-Dependent Multifunctional Enzyme
Maurice, M. S., Reinhardt, L. A., Surinya, K. H., Attwood, P. V., Wallace, J. C., Cleland, W. W., & Rayment, I. (2007) · Science · doi:10.1126/science.1144504 · Cited by 151
Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy
Wolpaw, A. J., & Dang, C. V. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.006 · Cited by 151
Anaplerotic roles of pyruvate carboxylase in mammalian tissues
Jitrapakdee, S., Vidal-Puig, A., & Wallace, J. C. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5410-y · Cited by 149
Rais, R., Jančařík, A., Tenora, L., Nedelcovych, M., Alt, J., Englert, J., Rojas, C., Le, A., Elgogary, A., Tan, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01069 · Cited by 138
Self-citationChisolm, D. A., Savic, D., Moore, A. J., Ballesteros‐Tato, A., León, B., Crossman, D. K., Murre, C., Myers, R., & Weinmann, A. S. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.015 · Cited by 105
Stoffwechsel der weißen Blutzellen
Warburg, O. H., Gawehn, K., & Geissler, A.-W. (1958) · Zeitschrift für Naturforschung B · doi:10.1515/znb-1958-0806 · Cited by 102
Warburg, O. H., Gawehn, K., & Geissler, A.-W. (1958) · PubMed · Cited by 96
Pinkus, L. M. (1977) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(77)46049-x · Cited by 89
Metabolic Influences That Regulate Dendritic Cell Function in Tumors
Dong, H., & Bullock, T. N. J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00024 · Cited by 89
Fortner, J. G. (1957) · Cancer · doi:10.1002/1097-0142(195711/12)10:6 · Cited by 76
The MYC mRNA 3′‐UTR couples RNA polymerase II function to glutamine and ribonucleotide levels
Dejure, F. R., Royla, N., Herold, S., Kalb, J., Walz, S., Ade, C. P., Mastrobuoni, G., Vanselow, J. T., Schlösser, A., Wolf, E., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201796662 · Cited by 74
Earhart, R. H., Amato, D. J., Chang, A. Y.-C., Borden, E. C., Shiraki, M., Dowd, M. E., Comis, R. L., Davis, T. E., & Smith, T. J. (1990) · Investigational New Drugs · doi:10.1007/bf00216936 · Cited by 71
Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy
Rivadeneira, D. B., & Delgoffe, G. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0894 · Cited by 69
Species-dependent and site-specific intestinal metabolism of ester prodrugs
van Gelder, J., Shafiee, M., Clercq, E. D., PENNINCKX, F. M., den Mooter, G. V., Kinget, R., & Augustijns, P. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00507-x · Cited by 59
Mouse PVRIG Has CD8+ T Cell–Specific Coinhibitory Functions and Dampens Antitumor Immunity
Murter, B., Pan, X., Ophir, E., Alteber, Z., Azulay, M., Sen, R., Levy, O., Dassa, L., Vaknin, I., Kfir, T. F., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0460 · Cited by 55
Self-citationZhu, X., Nedelcovych, M. T., Thomas, A. G., Hasegawa, Y., Moreno-Megui, A., Coomer, W., Vohra, V., Saito, A., Perez, G., Wu, Y., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0177-7 · Cited by 53
Self-citationLynch, G., Kemeny, N., & Casper, E. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198210000-00014 · Cited by 53
Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer
Shevchenko, I., & Bazhin, A. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01816 · Cited by 47
Nedelcovych, M. T., Kim, B.-H., Zhu, X., Lovell, L. E., Manning, A. A., Kelschenbach, J., Hadas, E., Chao, W., Prchalová, E., Dash, R. P., et al. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09859-w · Cited by 41
Self-citationKouidhi, S., Noman, M. Z., Kiéda, C., Elgaaïed, A. B., & Chouaïb, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00114 · Cited by 39
Kohan, A. B., Talukdar, I., Walsh, C. M., & Salati, L. M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.130 · Cited by 37
Einige Übereinstimmungen im Stoffwechsel der Carcinomzellen und Exsudatleukocyten
Bakker, A. (1927) · Journal of Molecular Medicine · doi:10.1007/bf01710710 · Cited by 27
MYC and AMPK–Save Energy or Die!
Haikala, H. M., Anttila, J. M., & Klefström, J. T. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00038 · Cited by 25
Veterans Administration Cancer Chemotherapy Study Group, Krantz, S., Rivers, S. L., Dwight, R. W., Corbus, H. F., Wolf, J., Green, I., Spear, P. W., Imperato, L., Lobe, S., et al. (1959) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/22.2.433 · Cited by 24
Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases
Fu, J., Pacyniak, E., Leed, M. G. D., Sadgrove, M. P., Marson, L., & Jay, M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24632 · Cited by 23
Phase II study on DON in patients with previously treated advanced lung cancer.
Eagan, R. T., Frytak, S., Wc, N., Et, C., & Ingle, J. N. (1982) · PubMed · Cited by 22
Gross, M. I., Chen, J., Englert, J., Janes, J. R., Leone, R. D., MacKinnon, A. L., Parlati, F., Rodriquez, M., Shwonek, P. J., & Powell, J. D. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2329 · Cited by 21
Self-citationK. Henke, Developmental Biologist
Caspari, E. W. (1957) · Science · doi:10.1126/science.125.3257.1076 · Cited by 4
Flagged first, then by citations
Cited by
Sorted by citations
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
“But a recent DON analog, JHU083, is a prodrug that is activated in the tumor microenvironment, improving the therapeutic window (118).”
BackgroundCancer metabolism: looking forward
Martínez‐Reyes, I., & Chandel, N. S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,877
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
The cancer metabolic reprogramming and immune response
Xia, L., Oyang, L., Lin, J., Tan, S., Han, Y., Wu, N., Yi, P., Tang, L., Pan, Q., Rao, S., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01316-8 · Cited by 1,312
“Powell and his team found that blocking glutamine can induce different metabolic processes, thereby overcoming the immune escape of tumors [81].”
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Metadata
- Authors
- Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., Tam, A., Blosser, R. L., Prchalova, E., Alt, J., Rais, R., Slusher, B. S., & Powell, J. D.
- Affiliations
- Johns Hopkins University (US)
- Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
- Corresponding author
- Powell, Jonathan D.
- ORCID
- Venue
- Science
- Published
- 2019-11-22
- Volume
- 366
- Issue
- 6468
- Pages
- 1013-1021
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7023461
- OpenAlex
- W2985764787
- Cited by
- 1,169
- References
- 57
- Citations by year
- 2026: 143 · 2025: 196 · 2024: 195 · 2023: 181 · 2022: 197 · 2021: 160 · 2020: 92 · 2019: 4
- FWCI
- 35.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH Office of the Director (R01CA226765, R01CA229451)
- The Bloomberg∼Kimmel Institute for Cancer Immunotherapy.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- glutamine antagonist, tumor immune evasion, tumor microenvironment, cancer metabolism, oxidative metabolism, glycolysis, tumor hypoxia, tumor acidosis, effector T cells, antitumor immunity, metabolic checkpoint, cancer immunotherapy
- MeSH terms
- Animals, Azo Compounds, Caproates, Citric Acid Cycle, Energy Metabolism, Female, Glucose, Glutamine, Immunologic Memory, Lymphocyte Activation, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Experimental, Immunotherapy, Adoptive, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Escape, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
